Int J Stomatol ›› 2024, Vol. 51 ›› Issue (1): 21-27.doi: 10.7518/gikq.2024021
• Oral Oncology • Previous Articles Next Articles
Liu Shiyi(),Chen Zhong(
),Zhang Suxin
CLC Number:
1 | Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J].Nat Rev Dis Primers, 2020, 6(1): 1-22. |
2 | Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3 680 patients[J]. J Natl Cancer Inst, 2016, 108(6): djv403. |
3 | Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice[J]. Nat Rev Immunol, 2020, 20(11): 651-668. |
4 | Kumar H. Progresses in immunotherapy[J]. Int Rev Immunol, 2020, 39(5): 203-204. |
5 | Gibson-Corley KN, Coppock J, Espinosa-Cotton M, et al. Clinical significance of activating interleu-kin 1 ligands in HPV-positive and HPV-negative HNSCCs[J]. FASEB J, 2020, 34(S1): 1. |
6 | Cochicho D, Esteves S, Rito M, et al. PIK3CA gene mutations in HNSCC: systematic review and correlations with HPV status and patient survival[J]. Cancers (Basel), 2022, 14(5): 1286. |
7 | von Witzleben A, Wang C, Laban S, et al. HNSCC: tumour antigens and their targeting by immunotherapy[J]. Cells, 2020, 9(9): 2103. |
8 | D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer[J]. N Engl J Med, 2007, 356(19): 1944-1956. |
9 | Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(2): 467-475. |
10 | Hoppe-Seyler K, Bossler F, Braun JA, et al. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets[J]. Trends Microbiol, 2018, 26(2): 158-168. |
11 | Rietbergen MM, Snijders PJ, Beekzada D, et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas[J]. Int J Cancer, 2014, 134(10): 2366-2372. |
12 | Dok R, Glorieux M, Holacka K, et al. Dual role for p16 in the metastasis process of HPV positive head and neck cancers[J]. Mol Cancer, 2017, 16(1): 113. |
13 | Sewell A, Brown B, Biktasova A, et al. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer[J]. Clin Cancer Res, 2014, 20(9): 2300-2311. |
14 | Devaraja K, Aggarwal S, Verma SS, et al. Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma: a co-mprehensive update[J]. Life Sci, 2020, 245: 117383. |
15 | Zhang JL, Chen T, Yang XP, et al. Attenuated TRAF3 fosters activation of alternative NF-κB and reduced expression of antiviral interferon, TP53, and RB to promote HPV-positive head and neck cancers[J]. Cancer Res, 2018, 78(16): 4613-4626. |
16 | Faden DL, Ding F, Lin Y, et al. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma[J]. Oral Oncol, 2019, 96: 140-147. |
17 | Combes JD, Dalstein V, Gheit T, et al. Prevalence of human papillomavirus in tonsil brushings and gargles in cancer-free patients: the SPLIT study[J]. Oral Oncol, 2017, 66: 52-57. |
18 | Li BN, Sui L. Metabolic reprogramming in cervical cancer and metabolomics perspectives[J]. Nutr Metab (Lond), 2021, 18(1): 93. |
19 | Kahue CN, Jerrell RJ, Parekh A. Expression of human papillomavirus oncoproteins E6 and E7 inhi-bits invadopodia activity but promotes cell migration in HPV-positive head and neck squamous cell carcinoma cells[J]. Cancer Rep (Hoboken), 2018, 1(3): e1125. |
20 | Wang BZ, Zhang SW, Tong FJ, et al. HPV+HNSCC-derived exosomal miR-9-5p inhibits TGF-β signa-ling-mediated fibroblast phenotypic transformation through NOX4[J]. Cancer Sci, 2022, 113(4): 1475-1487. |
21 | Lechner A, Schlößer HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2019, 8(3): 1535293. |
22 | Chatfield-Reed K, Gui SY, O’Neill WQ, et al. HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes[J]. Oral Oncol, 2020, 100: 104488. |
23 | Hladíková K, Koucký V, Bouček J, et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells[J]. J Immunother Cancer, 2019, 7(1): 261. |
24 | Ruffin AT, Cillo AR, Tabib T, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma[J]. Nat Commun, 2021, 12(1): 3349. |
25 | Forster MD, Devlin MJ. Immune checkpoint inhibition in head and neck cancer[J]. Front Oncol, 2018, 8: 310. |
26 | Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, et al. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis[J]. Oral Oncol, 2020, 106: 104722. |
27 | Hwan KM, Jae-Hwan K, Min L, et al. Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune check-point blockade response[J]. Br J Cancer, 2020, 122(11): 1649-1660. |
28 | Wang J, Sun H, Zeng Q, et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma[J]. Sci Rep, 2019, 9(1): 13404. |
29 | Cillo AR, Kürten CHL, Tabib T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer[J]. Immunity, 2020, 52(1): 183-199.e9. |
30 | Zagozdzon R, Winiarska M, Firczuk M. Immune evasion as the main challenge for immunotherapy of cancer[J]. Cancers (Basel), 2022, 14(15): 3622. |
31 | Li FG, Deng LG, Jackson KR, et al. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations[J]. J Immunother Cancer, 2021, 9(7): e002531. |
32 | Sanchez-Canteli M, Hermida-Prado F, Sordo-Bahamonde C, et al. Lectin-like transcript 1 (LLT1) checkpoint: a novel independent prognostic factor in HPV-negative oropharyngeal squamous cell carcinoma[J]. Biomedicines, 2020, 8(12): 535. |
33 | Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuxi-mab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. |
34 | Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965. |
35 | Ferris RL, Blumenschein G, Fayette J, et al. Nivo-lumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. |
[1] | Li Hongfang,Chen Zhong,Zhang Suxin.. Research progress on immune checkpoint inhibitor combined with radiotherapy in head and neck squamous cell carcinoma [J]. Int J Stomatol, 2022, 49(5): 614-620. |
[2] | Hao Fu,Sun Rui. Research progress on second primary carcinoma of head and neck squamous cell carcinoma [J]. Int J Stomatol, 2019, 46(5): 585-592. |
[3] | Zhang Xu, Xu Enxin, Ruan Min.. Correlation between Toll-like receptor 9 and head and neck squamous cell carcinoma [J]. Inter J Stomatol, 2017, 44(5): 596-601. |
[4] | Fang Juan, Song Jingjing, Ma Da, Wang Yanqiong, Zhou Fangjing, Wang Zhi. An example for the application of data-mining from Oncomine database in the research of head and neck squamous cell carcinoma [J]. Inter J Stomatol, 2014, 41(6): 647-651. |
[5] | Sun Yunfeng1, Jiang Tong2, Chen Chuanjun1. Relation of human papillomavirus and oral cancer and type 16E5 gene [J]. Inter J Stomatol, 2014, 41(5): 609-612. |
[6] | Zhang Jing1, Zhou Gang1,2.. Programmed death -1/programmed death -ligand 1 pathway and its regulation on oral chronic diseases [J]. Inter J Stomatol, 2012, 39(1): 69-72. |
[7] | HE Zhi-feng, WANG Zhi-yong, HU Qin -gang.. Research progress of dendritic cell and dendritic cell function and vaccine [J]. Inter J Stomatol, 2010, 37(6): 672-676. |
[8] | YANG Wen-yu1, JIANG Tong2, CHEN Chuan-jun1.. Research progress on high-risk type human papillomavirus 16 E5 gene in the pathogenesis of oral cancer [J]. Inter J Stomatol, 2010, 37(6): 691-694. |
[9] | SUN Shun-tao, YANG Hong-yu. Roles of 4-1BB and 4-1BB ligand in oral cancer immunotherapy [J]. Inter J Stomatol, 2009, 36(3): 319-322. |
[10] | WU Ting, SUN Qin -feng, YANG Pi -shan. Association between periodontal disease and Th1/Th2 [J]. Inter J Stomatol, 2009, 36(2): 197-197~200. |
[11] | LI Yi- lei, FAN Ming- wen. Advances in immunother apy of tongue squamous cell car cinoma [J]. Inter J Stomatol, 2008, 35(4): 444-444~. |
[12] | YIN Dong, GAO Zhi.. Study of Chemokine and Its Receptor in Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma [J]. Inter J Stomatol, 2007, 34(03): 203-206. |